Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the application. Please amend claim 177 as follows.

Listing of the Claims

1. (Previously Presented) A compound of Formula (**I**):



(I)

wherein:

W is a straight or branched chain C_{1-5} alkylene group optionally containing one double bond or one triple bond, wherein said C_{1-5} alkylene group is optionally substituted with halogen, hydroxyl, C_{1-4} alkyl, C_{1-4} haloalkyl or C_{1-4} alkoxy;

Y is a straight or branched chain C_{1-5} alkylene group optionally containing one double bond, or one triple bond or carbonyl, wherein said C_{1-5} alkylene group is optionally substituted with halogen, hydroxyl, C_{1-4} alkyl, C_{1-4} haloalkyl or C_{1-4} alkoxy;

X is $-NR_3C(O)-$, $-C(O)NR_3$, $-NR_3S(O)_2-$, $-S(O)_2NR_3-$, $-NR_3C(O)NR_4-$, $-NR_3C(O)O-$, $-OC(O)NR_3-$, $-NR_3-$, -CH(OH)-, - C(NH)-, - O-, -S-, - S(O)- or $-S(O)_2-$;

R_3 and R_4 are independently H, C_{1-4} alkyl, phenyl or heteroaryl, wherein each of said alkyl, phenyl and heteroaryl are optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, hydroxyl, thiol, cyano, nitro, C_{1-4} haloalkyl, amino, C_{1-4} alkylamino, di-C_{1-4}-alkylamino, C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} haloalkoxy, C_{1-4} alkylthio, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfonyl, C_{1-4} haloalkylthio, C_{1-4} haloalkylsulfinyl and C_{1-4} haloalkylsulfonyl;

Z is H, halogen, phenyl or heteroaryl, wherein said phenyl and heteroaryl are optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, hydroxy, thiol, cyano, nitro, C_{1-4} haloalkyl, amino, C_{1-4} alkylamino, di-C_{1-4}-

alkylamino, C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} haloalkoxy, C_{1-4} alkylthio, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfonyl, C_{1-4} haloalkylthio, C_{1-4} haloalkylsulfinyl and C_{1-4} haloalkylsulfonyl;

R_1 is H, halogen, C_{1-4} alkyl or C_{1-4} haloalkyl;

R_2 is H or C_{1-8} alkyl and

"n" and "m" are each 1; or

a pharmaceutically acceptable salt, solvate or hydrate thereof;

provided that:

v) when R_1 is H and R_2 is CH_3 then $-[W]_n$-X-$[Y]_m$-Z together is not 2,6-dichloro-4-trifluoromethylphenoxy, C(O)NH-C_6H_4-*p*-OCH_2CH_3, $NHC(O)CH(CH_3)_2$, SCH_3, C(O)-C_6H_4-*p*-O-C_8H_{17}, SCH_2CH_3, $C(O)NHC_6H_5$, $CH(OCH_3)_2$, $CH_2OC(O)CH_3$, CO_2H, CO_2CH_3, $C(O)C_6H_4$-*p*-NO_2, $C(O)C_6H_5$, $CH_2CH_2CO_2CH_3$, $CH_2CH_2CH_2CH_2CO_2CH_3$, $CH_2CH_2CH_2CO_2CH_3$ and $CH_2CO_2CH_3$;

viii) when R_1 is H and R_2 is CH_2CH_3 then $-[W]_n$-X-$[Y]_m$-Z together is not $CH_2SCH_2CH_3$, $OCH_2CH_2CH=CH_2$, $CH_2CH_2CH_2OH$, CH_2CH_2CHO, $CO_2CH_2CH_3$, OCH_3, $C(O)CH_2Br$, $CO_2C_8H_{17}$, formyl, OH, $CH_2N(CH_2CH_2Cl)_2$, $CH(CH_3)OC(O)CH_3$, CH_2OH, $CH_2OC(O)CH_3$, $C(O)CH_3$, $C(O)C_6H_5$ and $C(O)NHCH_2CO_2CH_2CH_3$.

2-151. (Canceled)

152. (Previously Presented) The compound according to claim 1 wherein W is the straight or branched C_{1-5} alkylene group optionally containing one double bond, one triple bond or carbonyl, wherein said C_{1-5} alkylene group is optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.

153. (Previously Presented) The compound according to claim 1 wherein W is selected from the group consisting of $-CH_2-$, $-CH_2CH_2-$, $-CH(CH_3)CH_2-$, $-CH_2CH(CH_3)-$, $-C(CH_3)_2CH_2-$, $-CH_2C(CH_3)_2-$, $-CH_2CH_2CH_2-$, and $-CH_2CH_2CH_2CH_2-$, each optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.

154. (Previously Presented) The compound according to claim 1 wherein W is $-CH(CH_3)-$,

-$CH(OCH_3)CH_2$-, or -$CH_2CH(OCH_3)$-, each optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.

155. (Previously Presented) The compound according to claim 1 wherein W is selected from the group consisting of -CH_2-, -$CH(CH_3)$-, -$C(CH_3)_2$-,-CH_2CH_2-, -$CH(CH_3)CH_2$-, -$CH_2CH(CH_3)$-, -$C(CH_3)_2CH_2$-, -$CH_2C(CH_3)_2$-, -$CH(OCH_3)CH_2$-, -$CH_2CH(OCH_3)$-, -$CH_2CH_2CH_2$-, and -$CH_2CH_2CH_2CH_2$.

156. (Previously Presented) The compound according to claim 1 wherein W is -CH=CH- or -C≡ C.

157. (Previously Presented) The compound according to claim 1 wherein Y is the straight or branched chain C_{1-5} alkylene group optionally containing one double bond, one triple bond or carbonyl, wherein said C_{1-5} alkylene group is optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.

158. (Previously Presented) The compound according to claim 1 wherein Y is selected from the group consisting of -CH_2-, -CH_2CH_2-, -$CH(CH_3)CH_2$-, -$CH_2CH(CH_3)$-, -$C(CH_3)_2CH_2$-, -$CH_2C(CH_3)_2$-, -$CH_2CH_2CH_2$-, -$CH_2CH_2CH_2CH_2$-, -C≡ CCH_2-, -CH_2C≡ C-, -$CH_2C(O)$-, -$C(O)CH_2$-, -$CH(CH_3)C(O)$-, -$C(O)CH(CH_3)$-, -$CH_2CH_2C(O)$-, -$C(O)CH_2CH_2$-, -$C(CH_3)_2CH_2C(O)$-, -$C(O)CH_2C(CH_3)_2$-, -$CH_2C(O)CH_2$-, -$CH_2CH_2CH_2C(O)$-, -$C(O)CH_2CH_2CH_2$-, -$CH(CH_3)CH_2CH_2C(O)$-, -$C(O)CH_2CH_2CH(CH_3)$-, -$CH_2CH_2C(O)CH_2$-, -$CH_2C(O)CH_2CH_2$-, -CH=CHC(O)-, -C(O)CH=CH-, -$C(CH_3)$=CHC(O)-, and -C(O)CH=$C(CH_3)$-, each optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.

159. (Previously Presented) The compound according to claim 1 wherein Y is selected from the group consisting of -CH_2-, -CH_2CH_2-, -$CH(CH_3)CH_2$-, -$CH_2CH(CH_3)$-, -$C(CH_3)_2CH_2$-, -$CH_2C(CH_3)_2$-, -$CH_2CH_2CH_2$-, -$CH_2CH_2CH_2CH_2$-, -C≡ CCH_2-, -CH_2C≡ C-, -$CH_2C(O)$-, -$C(O)CH_2$-, -$CH(CH_3)C(O)$-, -$C(O)CH(CH_3)$-, -$CH_2CH_2C(O)$-, -$C(O)CH_2CH_2$-, -$C(CH_3)_2CH_2C(O)$-, -$C(O)CH_2C(CH_3)_2$-, -$CH_2C(O)CH_2$-, -$CH_2CH_2CH_2C(O)$-, -$C(O)CH_2CH_2CH_2$-, -$CH(CH_3)CH_2CH_2C(O)$-, -$C(O)CH_2CH_2CH(CH_3)$-, -$CH_2CH_2C(O)CH_2$-, -$CH_2C(O)CH_2CH_2$-, -CH=CHC(O)-, -C(O)CH=CH-, -$C(CH_3)$=CHC(O)-, and -C(O)CH=$C(CH_3)$-.

160. (Previously Presented) The compound according to claim 1 wherein Y is -$CH(CH_3)$- optionally substituted with halogen, hydroxyl or C_{1-4} alkoxy.

161. (Previously Presented) The compound according to claim 1 wherein Y is -$CH(OCH_3)CH_2$- or -$CH_2CH(OCH_3)$- optionally substituted with halogen, hydroxyl or C_{1-4} alkyl.

162. (Previously Presented) The compound according to claim 1 wherein Y is -CH=CH- optionally substituted with C_{1-4} alkyl or C_{1-4} alkoxy.

163. (Previously Presented) The compound according to claim 1 wherein Y is -$C(CH_3)_2$-, -C≡ C-, -C(O)-, -$C(CH_3)_2C(O)$-, or -$C(O)C(CH_3)_2$-.

164. (Previously Presented) The compound according to claim 1 wherein X is -NHC(O)- or -C(O)NH-.

165. (Withdrawn) The compound according to claim 1 wherein X is -NH- or -NCH_3-.

166. (Previously Presented) The compound according to claim 1 wherein X is selected from the group consisting of CH(OH)-, -C(NH)-, -O-, -S-, -S(O)-, or -$S(O)_2$-.

167. (Previously Presented) The compound according to claim 1 wherein Z is H, halogen, or phenyl.

168. (Previously Presented) The compound according to claim 1 wherein Z is phenyl optionally substituted with 1 to 3 substituents selected from the group consisting of -F, -Cl, -Br, -CF_3, -$NHCH_3$, -$N(CH_3)_2$, -CH_3, -CH_2CH_3, -OCH_3 and -OCF_3.

169. (Previously Presented) The compound according to claim 1 wherein Z is heteroaryl optionally substituted with 1 to 3 substituents selected from the group consisting of -F, -Cl, -Br, -CF_3, -$NHCH_3$, -$N(CH_3)_2$, -CH_3, -CH_2CH_3, -OCH_3 and -OCF_3.

170. (Previously Presented) The compound according to claim 1 wherein R_1 is H.

171. (Canceled)

172. (Previously Presented) The compound according to claim 1 wherein R_1 is halogen.

173. (Previously Presented) The compound according to claim 1 wherein R_1 is C_{1-4} alkyl.

174. (Previously Presented) The compound according to claim 1 wherein R_1 is C_{1-4} haloalkyl.

175. (Previously Presented) The compound according to claim 1 wherein R_2 is H.

176. (Previously Presented) The compound according to claim 1 wherein R_2 is C_{1-8} alkyl.

177. (Currently Amended) The according to claim 1 selected from the group consisting of:

5-Ethylsulfanylmethyl-1H-pyrazole-3-carboxylic acid;

5-Ethanesulfinylmethyl-1H-pyrazole-3-carboxylic acid;

5-Ethanesulfonylmethyl-1H-pyrazole-3-carboxylic acid;

5-(2-Oxo-propoxymethyl)-1H-pyrazole-3-carboxylic acid;

5-Prop-2-ynyloxymethyl-1H-pyrazole-3-carboxylic acid;

5-(1-Methylsulfanyl-ethyl)-1H-pyrazole-3-carboxylic acid;

5-(1-Methanesulfinyl-ethyl)-1H-pyrazole-3-carboxylic acid;

5-(1-Methanesulfonyl-ethyl)-1H-pyrazole-3-carboxylic acid;

5-(1,1-Dimethoxy-ethyl)-1H-pyrazole-3-carboxylic acid;

5-(1-Acetoxy-ethyl)-1H-pyrazole-3-carboxylic acid;

5-Propylcarbamoylmethyl-1H-pyrazole-3-carboxylic acid;

5-(2-Dimethylamino-1-methyl-ethyl)-1H-pyrazole-3-carboxylic acid;

5-(2-Methoxy-vinyl)-1H-pyrazole-3-carboxylic acid;

5-(3-Acetoxy-propyl)-1H-pyrazole-3-carboxylic acid;

5-(2,2-Dimethoxy-ethyl)-1H-pyrazole-3-carboxylic acid;

5-(2-Imino-propyl)-1H-pyrazole-3-carboxylic acid;

5-Methoxymethyl-1H-pyrazole-3-carboxylic acid;

5-Ethoxymethyl-1H-pyrazole-3-carboxylic acid;

5-(2-Methoxy-ethyl)-1H-pyrazole-3-carboxylic acid;

5-(3-Methoxy-propyl)-1H-pyrazole-3-carboxylic acid;

5-Methylsulfanylmethyl-1H-pyrazole-3-carboxylic acid;

5-Methanesulfinylmethyl-1H-pyrazole-3-carboxylic acid;

5-Methanesulfonylmethyl-1H-pyrazole-3-carboxylic acid;

5-(2-Methylsulfanyl-ethyl)-1H-pyrazole-3-carboxylic acid;

5-(2-Methanesulfinyl-ethyl)-1H-pyrazole-3-carboxylic acid;

5-(2-Methanesulfonyl-ethyl)-1H-pyrazole-3-carboxylic acid;

5-(3-Methylsulfanyl-propyl)-1H-pyrazole-3-carboxylic acid;

5-(3-Methanesulfinyl-propyl)-1H-pyrazole-3-carboxylic acid;

5-(3-Methanesulfonyl-propyl)-1H-pyrazole-3-carboxylic acid;

5-(2-Methylamino-ethyl)-1H-pyrazole-3-carboxylic acid;

5-(2-Dimethylamino-ethyl)-1H-pyrazole-3-carboxylic acid;

5-(Benzylamino-methyl)-1H-pyrazole-3-carboxylic acid;

5-Methoxymethyl-1H-pyrazole-3-carboxylic acid;

5-Ethoxymethyl-1H-pyrazole-3-carboxylic acid; [[or]] and

5-(2,2-Diethoxy-ethyl)-1H-pyrazole-3-carboxylic acid; or

a pharmaceutically acceptable salt, solvate or hydrate thereof.

178. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier in combination with at least one compound according to Formula (I):



(I)

wherein:

W is a straight or branched chain C_{1-5} alkylene group optionally containing one double bond or one triple bond, wherein said C_{1-5} alkylene group is optionally substituted with halogen, hydroxyl, C_{1-4} alkyl, C_{1-4} haloalkyl or C_{1-4} alkoxy;

Y is a straight or branched chain C_{1-5} alkylene group optionally containing one double bond, or one triple bond or carbonyl, wherein said C_{1-5} alkylene group is optionally substituted with halogen, hydroxyl, C_{1-4} alkyl, C_{1-4} haloalkyl or C_{1-4} alkoxy;

X is $-NR_3C(O)-$, $-C(O)NR_3$, $-NR_3S(O)_2-$, $-S(O)_2NR_3-$, $-NR_3C(O)NR_4-$, $-NR_3C(O)O-$, $-OC(O)NR_3-$, $-NR_3-$, -CH(OH)-, - C(NH)-, - O-, -S-, - S(O)- or $-S(O)_2-$;

R_3 and R_4 are independently H, C_{1-4} alkyl, phenyl or heteroaryl, wherein each of said alkyl, phenyl and heteroaryl are optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, hydroxyl, thiol, cyano, nitro, C_{1-4} haloalkyl, amino, C_{1-4} alkylamino, di-C_{1-4}-alkylamino, C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} haloalkoxy, C_{1-4} alkylthio, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfonyl, C_{1-4} haloalkylthio, C_{1-4} haloalkylsulfinyl and C_{1-4} haloalkylsulfonyl;

Z is H, halogen, phenyl or heteroaryl, wherein said phenyl and heteroaryl are optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, hydroxy, thiol, cyano, nitro, C_{1-4} haloalkyl, amino, C_{1-4} alkylamino, di-C_{1-4}-alkylamino, C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} haloalkoxy, C_{1-4} alkylthio, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfonyl, C_{1-4} haloalkylthio, C_{1-4} haloalkylsulfinyl and C_{1-4} haloalkylsulfonyl;

R_1 is H, halogen, C_{1-4} alkyl or C_{1-4} haloalkyl;

R_2 is H or C_{1-8} alkyl and

"n" and "m" are each 1; or

a pharmaceutically acceptable salt, solvate or hydrate thereof.

179. (Withdrawn) A method for prophylaxis or treatment of a metabolic-related disorder in an individual in need of said prophylaxis or treatment comprising administering to the individual a therapeutically effective amount of a compound according to claim 1 or a pharmaceutical composition according to claim 178.

180. (Withdrawn) The method according to claim 179 wherein the metabolic-related disorder is selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease,

insulin resistance, obesity, impaired glucose tolerance, atheromatous disease, hypertension, stroke, Syndrome X, heart disease and type 2 diabetes.

181. (Withdrawn) The method according to claim 180 wherein the metabolic-related disorder is dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes.

182. (Withdrawn) The method according to claim 180 wherein the metabolic-related disorder is dyslipidemia.

183. (Withdrawn) The method according to claim 180 wherein the metabolic-related disorder is atherosclerosis.

184. (Withdrawn) The method according to claim 180 wherein the metabolic-related disorder is coronary heart disease.

185. (Withdrawn) The method according to claim 180 wherein the metabolic-related disorder is insulin resistance.

186. (Withdrawn) The method according to claim 180 wherein the metabolic-related disorder is type 2 diabetes.

187. (Withdrawn) The method of producing a pharmaceutical composition comprising admixing at least one compound according to claim 1 and a pharmaceutically acceptable carrier or excipient.